10-K: Inogen Reports Increased Sales Revenue in 2024, Driven by International Growth

Inogen's 2024 10-K filing reveals a 6.4% increase in total revenue, driven by a surge in international and domestic business-to-business sales, alongside strategic shifts in management and product development.

Summary

• Inogen's 10-K filing for the fiscal year ended December 31, 2024, reports a 6.4% increase in total revenue, reaching $335.7 million compared to $315.66 million in 2023.
• Sales revenue increased by 10.8% to $278.756 million, driven by higher international and domestic business-to-business sales.
• Rental revenue decreased by 11.1% to $56.949 million, primarily due to a higher mix of lower private-payor reimbursement rates.
• The company sold approximately 157,500 oxygen systems in 2024, a 20.7% increase from the 130,500 systems sold in 2023.
• Gross margin on sales revenue increased to 46.7% from 37.0%, attributed to lower material costs and operational efficiencies.
• Gross margin on rental revenue decreased to 43.3% from 52.7%, due to a higher mix of private-payor reimbursement, lower net revenue per rental patient, and higher service costs.
• Research and development expenses increased by 3.7% to $21.61 million.
• Sales and marketing expenses decreased by 3.8% to $103.069 million.
• The company reported a net loss of $35.888 million, a significant decrease from the $102.449 million net loss in the previous year, primarily due to lower goodwill impairment, material cost reductions and higher sales revenue.
• As of December 31, 2024, Inogen had cash and cash equivalents of $113.8 million.
• The company expects its existing capital resources and cash generated from sales and rentals to meet its operating and investing requirements for at least the next twelve months.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. While the company shows improved financial performance with increased sales revenue and a reduced net loss, there are still challenges with rental revenue and a competitive market. The strategic collaboration with Yuwell and the capital raise are positive developments.

Positives

• Sales revenue increased by 10.8% due to higher international and domestic business-to-business sales.
• Gross margin on sales revenue increased to 46.7% due to lower material costs and operational efficiencies.
• Net loss significantly decreased to $35.888 million from $102.449 million in the prior year.
• The company launched the Inogen Rove 4 in the U.S. and European Union in October 2024.
• Inogen obtained 510(k) clearance for the Simeox airway clearance system on December 23, 2024.

Negatives

• Rental revenue decreased by 11.1% due to lower private payor reimbursement rates.
• Gross margin on rental revenue decreased to 43.3% from 52.7%, due to a higher mix of private-payor reimbursement, lower net revenue per rental patient, and higher service costs.

Risks

• The respiratory market is highly competitive.
• The company depends on a limited number of customers for a significant portion of its sales revenue.
• Reduction or interruption in the supply of components and products may adversely affect manufacturing operations.
• Changes to reimbursement rates, payment methodologies, or coverage policies for products by government or commercial payors may adversely affect the business.
• The company is subject to extensive federal and state regulation, and failure to comply with applicable regulations could result in severe sanctions.
• The company's products could infringe or appear to infringe the intellectual property rights of others, which may lead to costly litigation.

Future Outlook

Inogen expects its existing capital resources and cash generated from sales and rentals to be sufficient to meet its operating and investing requirements for at least the next 12 months. The company plans to continue investing in product development, expanding its sales teams, and pursuing strategic acquisitions.

Management Comments

• The company is focused on expanding new products that drive benefits to patients, prescribers and our customers with a clinically relevant pipeline.
• The company is continuing to focus on increased productivity driven by improved sales management discipline, insights-informed tools, and optimized patient lead generation with a downsized direct-to-consumer sales team.
• The company continues to evolve its operating model to focus the enhanced sales teams to drive increased rental revenue by establishing relationships with the prescriber through a consistent cadence of contact.

Industry Context

The long-term oxygen therapy market is highly competitive, with Inogen competing against numerous manufacturers and distributors of POCs, as well as providers of other long-term oxygen therapy solutions. The market is subject to rapid change resulting from technological advances, innovations and scientific discoveries.

Comparison to Industry Standards

• Significant manufacturing competitors are Caire Medical (a subsidiary of NGK Spark Plug), DeVilbiss Healthcare (a subsidiary of Drive Medical), O2 Concepts, Precision Medical, Gas Control Equipment (a subsidiary of Colfax), Nidek Medical, 3B Medical, SysMed, iRhythm Technologies, Inc., and Belluscura.
• Respironics (a subsidiary of Koninklijke Philips N.V.) announced in early 2024 that it was leaving the U.S. portable oxygen concentrator market until further regulatory assessments but continues to have product in the market.
• For many years, Lincare, Inc. (a subsidiary of the Linde Group), Apria Healthcare, Inc., AdaptHealth Corp., Rotech Healthcare, Inc., and Viemed Healthcare, Inc. have been among the market leaders in providing respiratory therapy products, while the remaining market is serviced by local providers.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is party to various legal proceedings and investigations arising in the normal course of business.

Stakeholder Impact

• The company's performance impacts shareholders through stock value and potential dividends.
• Employees are affected by changes in compensation, benefits, and job security.
• Customers benefit from innovative products and services.
• Suppliers are impacted by the company's purchasing decisions and payment terms.
• Creditors are affected by the company's ability to meet its financial obligations.

Next Steps

• The company intends to commercialize Simeox through the purchase of the product initially, followed by recurring sales of device disposables.
• The company will begin efforts to obtain reimbursement coverage in the first quarter of 2025 for the Simeox product in the U.S.

Key Dates